Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site.

ABSTRACT:

Background

Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for all European registry donor transplants intended for the Australian-Pacific region. We examined properties of these transplants to ascertain how quality is maintained.

Methods

We analyzed 100 pandemic-related allogeneic mobilized blood-derived stem cell apheresis products generated at 30 collection sites throughout Europe, shipped to and cryopreserved at our center between April and November of 2020. Products were shipped in the cool, subsequently frozen with DMSO as cryoprotectant

SUBMITTER: Wiercinska E 

PROVIDER: S-EPMC8027980 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature